HSBC sees no earnings hit from FDA action on India's Aurobindo Pharma
BUZZ-HSBC sees no earnings hit from FDA action on India's Aurobindo Pharma ** HSBC says it does not expect Aurobindo Pharma ARBN.NS to face near-term sales or earnings hit from the U.S. FDA flagging issues at its Eugia Unit 3 facility
** The company's stock is down 0.4% at 1,402.6 rupees
** The FDA last week flagged gaps in the facility's manufacturing quality standards and tagged it as 'Official Action Indicated'
** While the tag does not stop existing production, it acts as a hurdle against new drug approvals until the issues are resolved
** "There is limited dependency on Eugia 3 plant for new approvals," the brokerage said
** HSBC maintained its "buy" rating and target price of 1,580 rupees
** Nine other brokerages rate the stock "buy"; the median PT of 27 is 1,550 rupees - data compiled by LSEG
** YTD, ARBN up 18.5%
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma USA Receives FTC Approval To Acquire Lannett Company
Brief: Aurobindo Pharma Obtains US FTC Approval For Lannett Acquisition
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett (updated)
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc.
HSBC sees no earnings hit from FDA action on India's Aurobindo Pharma